Several ADAM17 inhibitors have been screened for cancer research, but the high homology between metalloproteinases active sites has limited the development of highly specific ADAM17 small molecule inhibitors, and the clinical use has been limited due to its potential side effects (Rossello et al., 2016). Here, ADAM17 is linked to cancer.